BindingDB logo
myBDB logout

Patent code US11066360

Compile Data Set for Download or QSAR
Found 104 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Plasma kallikrein


(Homo sapiens (Human))
BDBM433423
PNG
(US10562850, Compound 55a | US11066360, Compound 55...)
Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NS(C)(=O)=O)c1ccncc1
Show InChI InChI=1S/C31H36ClFN6O5S/c1-3-44-24-17-27(39(19-24)30(41)37-28-9-7-23(32)18-35-28)29(40)36-26-16-22(6-8-25(26)33)31(38-45(2,42)43,13-10-20-4-5-20)21-11-14-34-15-12-21/h6-9,11-12,14-16,18,20,24,27,38H,3-5,10,13,17,19H2,1-2H3,(H,36,40)(H,35,37,41)/t24-,27-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433422
PNG
(US10562850, Compound 71a | US11066360, Compound 71...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C30H33ClFN5O3/c1-40-24-17-27(37(18-24)29(39)35-23-7-5-22(31)6-8-23)28(38)36-26-16-21(4-9-25(26)32)30(33,13-10-19-2-3-19)20-11-14-34-15-12-20/h4-9,11-12,14-16,19,24,27H,2-3,10,13,17-18,33H2,1H3,(H,35,39)(H,36,38)/t24-,27-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433419
PNG
(US10562850, Compound 70c | US11066360, Compound 70...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C29H32ClFN6O3/c1-40-22-15-25(37(17-22)28(39)36-26-7-5-21(30)16-34-26)27(38)35-24-14-20(4-6-23(24)31)29(32,11-8-18-2-3-18)19-9-12-33-13-10-19/h4-7,9-10,12-14,16,18,22,25H,2-3,8,11,15,17,32H2,1H3,(H,35,38)(H,34,36,39)/t22-,25-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433370
PNG
(US10562850, Compound 18b | US11066360, Compound 18...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C31H32ClFN6O3/c1-42-24-15-27(39(18-24)30(41)38-28-10-8-23(32)17-36-28)29(40)37-26-14-22(7-9-25(26)33)31(35,12-11-19-5-6-19)21-4-2-3-20(13-21)16-34/h2-4,7-10,13-14,17,19,24,27H,5-6,11-12,15,18,35H2,1H3,(H,37,40)(H,36,38,41)/t24-,27-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433463
PNG
(US10562850, Compound 54g | US11066360, Compound 54...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)C(F)(F)F)c1
Show InChI InChI=1S/C29H29ClF4N6O3/c30-20-4-6-24(37-15-20)39-26(42)40-16-27(43,29(32,33)34)14-23(40)25(41)38-22-13-19(3-5-21(22)31)28(35,10-7-17-1-2-17)18-8-11-36-12-9-18/h3-6,8-9,11-13,15,17,23,43H,1-2,7,10,14,16,35H2,(H,38,41)(H,37,39,42)/t23-,27-,28?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433451
PNG
(US10562850, Compound 53d | US11066360, Compound 53...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2CC(F)(F)CN2C(=O)Nc2ccc(Cl)cn2)c1
Show InChI InChI=1S/C28H28ClF3N6O2/c29-20-4-6-24(35-15-20)37-26(40)38-16-27(31,32)14-23(38)25(39)36-22-13-19(3-5-21(22)30)28(33,10-7-17-1-2-17)18-8-11-34-12-9-18/h3-6,8-9,11-13,15,17,23H,1-2,7,10,14,16,33H2,(H,36,39)(H,35,37,40)/t23-,28?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433450
PNG
(US10562850, Compound 81h | US11066360, Compound 81...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)s1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C28H31ClFN5O3S/c1-38-20-15-23(35(16-20)27(37)34-25-7-6-24(29)39-25)26(36)33-22-14-19(4-5-21(22)30)28(31,11-8-17-2-3-17)18-9-12-32-13-10-18/h4-7,9-10,12-14,17,20,23H,2-3,8,11,15-16,31H2,1H3,(H,33,36)(H,34,37)/t20-,23-,28?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433403
PNG
(US10562850, Compound 34d | US11066360, Compound 34...)
Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1)c1ccccc1
Show InChI InChI=1S/C36H37ClFN5O3/c1-46-35(25-7-3-2-4-8-25)22-31(43(23-35)34(45)41-28-15-13-27(37)14-16-28)33(44)42-30-21-26(12-17-29(30)38)36(39,19-18-24-10-11-24)32-9-5-6-20-40-32/h2-9,12-17,20-21,24,31H,10-11,18-19,22-23,39H2,1H3,(H,41,45)(H,42,44)/t31-,35-,36?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433397
PNG
(US10562850, Compound 32a | US11066360, Compound 32...)
Show SMILES NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1)c1ccccn1
Show InChI InChI=1S/C34H34ClFN6O3/c35-25-12-14-30(39-20-25)41-32(44)42-21-33(45,23-6-2-1-3-7-23)19-28(42)31(43)40-27-18-24(11-13-26(27)36)34(37,16-15-22-9-10-22)29-8-4-5-17-38-29/h1-8,11-14,17-18,20,22,28,45H,9-10,15-16,19,21,37H2,(H,40,43)(H,39,41,44)/t28-,33-,34?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433385
PNG
(US10562850, Compound 65b | US11066360, Compound 65...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1
Show InChI InChI=1S/C30H33ClFN5O3/c1-40-23-17-26(37(18-23)29(39)35-22-10-8-21(31)9-11-22)28(38)36-25-16-20(7-12-24(25)32)30(33,14-13-19-5-6-19)27-4-2-3-15-34-27/h2-4,7-12,15-16,19,23,26H,5-6,13-14,17-18,33H2,1H3,(H,35,39)(H,36,38)/t23-,26-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433374
PNG
(US10562850, Compound 62c | US11066360, Compound 62...)
Show SMILES NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cn2)c1)c1ccccn1
Show InChI InChI=1S/C28H30ClFN6O3/c29-19-7-9-25(33-15-19)35-27(39)36-16-20(37)14-23(36)26(38)34-22-13-18(6-8-21(22)30)28(31,11-10-17-4-5-17)24-3-1-2-12-32-24/h1-3,6-9,12-13,15,17,20,23,37H,4-5,10-11,14,16,31H2,(H,34,38)(H,33,35,39)/t20-,23-,28?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433456
PNG
(US10562850, Compound 78a | US11066360, Compound 78...)
Show SMILES CCNC(CCC1CC1)(c1ccnc(C)c1)c1ccc(F)c(NC(=O)[C@H]2C[C@H](CN2C(=O)Nc2ccc(Cl)cn2)OC)c1
Show InChI InChI=1S/C32H38ClFN6O3/c1-4-37-32(13-11-21-5-6-21,23-12-14-35-20(2)15-23)22-7-9-26(34)27(16-22)38-30(41)28-17-25(43-3)19-40(28)31(42)39-29-10-8-24(33)18-36-29/h7-10,12,14-16,18,21,25,28,37H,4-6,11,13,17,19H2,1-3H3,(H,38,41)(H,36,39,42)/t25-,28-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433460
PNG
(US10562850, Compound 74a | US11066360, Compound 74...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NS(C)(=O)=O)c1ccncc1
Show InChI InChI=1S/C30H34ClFN6O5S/c1-43-23-16-26(38(18-23)29(40)36-27-8-6-22(31)17-34-27)28(39)35-25-15-21(5-7-24(25)32)30(37-44(2,41)42,12-9-19-3-4-19)20-10-13-33-14-11-20/h5-8,10-11,13-15,17,19,23,26,37H,3-4,9,12,16,18H2,1-2H3,(H,35,39)(H,34,36,40)/t23-,26-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433431
PNG
(US10562850, Compound 39h | US11066360, Compound 39...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1
Show InChI InChI=1S/C34H34ClFN6O3/c35-26-9-11-30(39-20-26)41-32(44)42-21-33(45,23-4-2-1-3-5-23)19-29(42)31(43)40-28-18-25(8-10-27(28)36)34(37,15-12-22-6-7-22)24-13-16-38-17-14-24/h1-5,8-11,13-14,16-18,20,22,29,45H,6-7,12,15,19,21,37H2,(H,40,43)(H,39,41,44)/t29-,33-,34?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433434
PNG
(US10562850, Compound 40a | US11066360, Compound 40...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1
Show InChI InChI=1S/C35H35ClFN5O3/c36-27-9-11-28(12-10-27)40-33(44)42-22-34(45,24-4-2-1-3-5-24)21-31(42)32(43)41-30-20-26(8-13-29(30)37)35(38,17-14-23-6-7-23)25-15-18-39-19-16-25/h1-5,8-13,15-16,18-20,23,31,45H,6-7,14,17,21-22,38H2,(H,40,44)(H,41,43)/t31-,34-,35?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433453
PNG
(US10562850, Compound 79a | US11066360, Compound 79...)
Show SMILES CNC(CCC1CC1)(c1ccnc(C)c1)c1ccc(F)c(NC(=O)[C@H]2C[C@H](CN2C(=O)Nc2ccc(Cl)cn2)OC)c1
Show InChI InChI=1S/C31H36ClFN6O3/c1-19-14-22(11-13-35-19)31(34-2,12-10-20-4-5-20)21-6-8-25(33)26(15-21)37-29(40)27-16-24(42-3)18-39(27)30(41)38-28-9-7-23(32)17-36-28/h6-9,11,13-15,17,20,24,27,34H,4-5,10,12,16,18H2,1-3H3,(H,37,40)(H,36,38,41)/t24-,27-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433466
PNG
(US10562850, Compound 42l | US11066360, Compound 42...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Cc1cc(ccc1F)C(CCC1CC1)n1ccccc1=O
Show InChI InChI=1S/C29H30ClFN5O4/c1-40-21-15-25(36(17-21)29(39)34-26-12-9-20(30)16-32-26)28(38)33-23-14-19(8-10-22(23)31)24(11-7-18-5-6-18)35-13-3-2-4-27(35)37/h2-4,8-10,12-14,16,18,21,24-25H,5-7,11,15,17H2,1H3,(H,32,34,39)/t21-,24?,25-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433382
PNG
(US10562850, Compound 64g | US11066360, Compound 64...)
Show SMILES NC(CCC1CC1)(c1cccnc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C29H31ClFN5O3/c30-21-6-8-22(9-7-21)34-28(39)36-17-23(37)15-26(36)27(38)35-25-14-19(5-10-24(25)31)29(32,12-11-18-3-4-18)20-2-1-13-33-16-20/h1-2,5-10,13-14,16,18,23,26,37H,3-4,11-12,15,17,32H2,(H,34,39)(H,35,38)/t23-,26-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433426
PNG
(US10562850, Compound 56a | US11066360, Compound 56...)
Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NC(C)=O)c1ccncc1
Show InChI InChI=1S/C32H36ClFN6O4/c1-3-44-25-17-28(40(19-25)31(43)38-29-9-7-24(33)18-36-29)30(42)37-27-16-23(6-8-26(27)34)32(39-20(2)41,13-10-21-4-5-21)22-11-14-35-15-12-22/h6-9,11-12,14-16,18,21,25,28H,3-5,10,13,17,19H2,1-2H3,(H,37,42)(H,39,41)(H,36,38,43)/t25-,28-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433432
PNG
(US10562850, Compound 57d | US11066360, Compound 57...)
Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)C(F)(F)F
Show InChI InChI=1S/C30H31ClF4N6O3/c1-44-28(30(33,34)35)15-24(41(17-28)27(43)40-25-7-5-21(31)16-38-25)26(42)39-23-14-20(4-6-22(23)32)29(36,11-8-18-2-3-18)19-9-12-37-13-10-19/h4-7,9-10,12-14,16,18,24H,2-3,8,11,15,17,36H2,1H3,(H,39,42)(H,38,40,43)/t24-,28-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433469
PNG
(US10562850, Compound 75e | US11066360, Compound 75...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cccc(c1)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C29H33ClN6O3/c1-39-24-16-25(36(18-24)28(38)35-26-8-7-22(30)17-33-26)27(37)34-23-4-2-3-21(15-23)29(31,12-9-19-5-6-19)20-10-13-32-14-11-20/h2-4,7-8,10-11,13-15,17,19,24-25H,5-6,9,12,16,18,31H2,1H3,(H,34,37)(H,33,35,38)/t24-,25-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433373
PNG
(US10562850, Compound 18a | US11066360, Compound 18...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@](=O)C(C)(C)C)c1cccc(c1)C#N
Show InChI InChI=1S/C35H40ClFN6O4S/c1-34(2,3)48(46)42-35(15-14-22-8-9-22,24-7-5-6-23(16-24)19-38)25-10-12-28(37)29(17-25)40-32(44)30-18-27(47-4)21-43(30)33(45)41-31-13-11-26(36)20-39-31/h5-7,10-13,16-17,20,22,27,30,42H,8-9,14-15,18,21H2,1-4H3,(H,40,44)(H,39,41,45)/t27-,30-,35?,48-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433416
PNG
(US10562850, Compound 69a | US11066360, Compound 69...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C29H31ClFN5O3/c30-21-4-6-22(7-5-21)34-28(39)36-17-23(37)16-26(36)27(38)35-25-15-20(3-8-24(25)31)29(32,12-9-18-1-2-18)19-10-13-33-14-11-19/h3-8,10-11,13-15,18,23,26,37H,1-2,9,12,16-17,32H2,(H,34,39)(H,35,38)/t23-,26-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433443
PNG
(US10562850, Compound 59d | US11066360, Compound 59...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)C2CC2)c1
Show InChI InChI=1S/C31H34ClFN6O3/c32-23-6-8-27(36-17-23)38-29(41)39-18-30(42,20-3-4-20)16-26(39)28(40)37-25-15-22(5-7-24(25)33)31(34,12-9-19-1-2-19)21-10-13-35-14-11-21/h5-8,10-11,13-15,17,19-20,26,42H,1-4,9,12,16,18,34H2,(H,37,40)(H,36,38,41)/t26-,30-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433454
PNG
(US10562850, Compound 51b | US11066360, Compound 51...)
Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C30H34ClFN6O3/c1-2-41-23-16-26(38(18-23)29(40)37-27-8-6-22(31)17-35-27)28(39)36-25-15-21(5-7-24(25)32)30(33,12-9-19-3-4-19)20-10-13-34-14-11-20/h5-8,10-11,13-15,17,19,23,26H,2-4,9,12,16,18,33H2,1H3,(H,36,39)(H,35,37,40)/t23-,26-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433388
PNG
(BDBM433391 | US10562850, Compound 36d | US10562850...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1
Show InChI InChI=1S/C29H32ClFN6O3/c1-40-21-15-24(37(17-21)28(39)36-26-10-8-20(30)16-34-26)27(38)35-23-14-19(7-9-22(23)31)29(32,12-11-18-5-6-18)25-4-2-3-13-33-25/h2-4,7-10,13-14,16,18,21,24H,5-6,11-12,15,17,32H2,1H3,(H,35,38)(H,34,36,39)/t21-,24-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433394
PNG
(US10562850, Compound 31i | US11066360, Compound 31...)
Show SMILES NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1)c1ccccn1
Show InChI InChI=1S/C35H35ClFN5O3/c36-26-12-14-27(15-13-26)40-33(44)42-22-34(45,24-6-2-1-3-7-24)21-30(42)32(43)41-29-20-25(11-16-28(29)37)35(38,18-17-23-9-10-23)31-8-4-5-19-39-31/h1-8,11-16,19-20,23,30,45H,9-10,17-18,21-22,38H2,(H,40,44)(H,41,43)/t30-,34-,35?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433412
PNG
(US10562850, Compound 29e | US11066360, Compound 29...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1
Show InChI InChI=1S/C36H34ClFN6O3/c37-28-12-14-32(41-21-28)43-34(46)44-22-35(47,25-6-2-1-3-7-25)19-31(44)33(45)42-30-18-27(11-13-29(30)38)36(40,16-15-23-9-10-23)26-8-4-5-24(17-26)20-39/h1-8,11-14,17-18,21,23,31,47H,9-10,15-16,19,22,40H2,(H,42,45)(H,41,43,46)/t31-,35-,36?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433418
PNG
(US10562850, Compound 72c | US11066360, Compound 72...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cn2)c1
Show InChI InChI=1S/C28H30ClFN6O3/c29-20-4-6-25(33-15-20)35-27(39)36-16-21(37)14-24(36)26(38)34-23-13-19(3-5-22(23)30)28(31,10-7-17-1-2-17)18-8-11-32-12-9-18/h3-6,8-9,11-13,15,17,21,24,37H,1-2,7,10,14,16,31H2,(H,34,38)(H,33,35,39)/t21-,24-,28?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433435
PNG
(US10562850, Compound 41a | US11066360, Compound 41...)
Show SMILES CNC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1
Show InChI InChI=1S/C35H36ClFN6O3/c1-38-35(16-13-23-7-8-23,25-14-17-39-18-15-25)26-9-11-28(37)29(19-26)41-32(44)30-20-34(46,24-5-3-2-4-6-24)22-43(30)33(45)42-31-12-10-27(36)21-40-31/h2-6,9-12,14-15,17-19,21,23,30,38,46H,7-8,13,16,20,22H2,1H3,(H,41,44)(H,40,42,45)/t30-,34-,35?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433439
PNG
(US10562850, Compound 58j | US11066360, Compound 58...)
Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C31H32ClFN6O3/c1-2-42-24-14-27(39(18-24)31(41)38-28-11-9-23(32)17-35-28)30(40)37-26-13-22(8-10-25(26)33)29(36-16-19-6-7-19)21-5-3-4-20(12-21)15-34/h3-5,8-13,17,19,24,27,29,36H,2,6-7,14,16,18H2,1H3,(H,37,40)(H,35,38,41)/t24-,27-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433448
PNG
(US10562850, Compound 52d | US11066360, Compound 52...)
Show SMILES CCCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C31H36ClFN6O3/c1-2-15-42-24-17-27(39(19-24)30(41)38-28-8-6-23(32)18-36-28)29(40)37-26-16-22(5-7-25(26)33)31(34,12-9-20-3-4-20)21-10-13-35-14-11-21/h5-8,10-11,13-14,16,18,20,24,27H,2-4,9,12,15,17,19,34H2,1H3,(H,37,40)(H,36,38,41)/t24-,27-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433413
PNG
(US10562850, Compound 68a | US11066360, Compound 68...)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C33H39ClFN5O4S/c1-32(2,3)45(44)39-33(15-12-21-4-5-21,22-13-16-36-17-14-22)23-6-11-27(35)28(18-23)38-30(42)29-19-26(41)20-40(29)31(43)37-25-9-7-24(34)8-10-25/h6-11,13-14,16-18,21,26,29,39,41H,4-5,12,15,19-20H2,1-3H3,(H,37,43)(H,38,42)/t26-,29-,33?,45-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433429
PNG
(US10562850, Compound 77a | US11066360, Compound 77...)
Show SMILES CCNC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@H](CN2C(=O)Nc2ccc(Cl)cn2)OC)c1
Show InChI InChI=1S/C31H36ClFN6O3/c1-3-36-31(13-10-20-4-5-20,21-11-14-34-15-12-21)22-6-8-25(33)26(16-22)37-29(40)27-17-24(42-2)19-39(27)30(41)38-28-9-7-23(32)18-35-28/h6-9,11-12,14-16,18,20,24,27,36H,3-5,10,13,17,19H2,1-2H3,(H,37,40)(H,35,38,41)/t24-,27-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433455
PNG
(US10562850, Compound 46k | US11066360, Compound 46...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccnc(C)c1
Show InChI InChI=1S/C30H34ClFN6O3/c1-18-13-21(10-12-34-18)30(33,11-9-19-3-4-19)20-5-7-24(32)25(14-20)36-28(39)26-15-23(41-2)17-38(26)29(40)37-27-8-6-22(31)16-35-27/h5-8,10,12-14,16,19,23,26H,3-4,9,11,15,17,33H2,1-2H3,(H,36,39)(H,35,37,40)/t23-,26-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433457
PNG
(US10562850, Compound 73a | US11066360, Compound 73...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NC(C)=O)c1ccncc1
Show InChI InChI=1S/C31H34ClFN6O4/c1-19(40)38-31(12-9-20-3-4-20,21-10-13-34-14-11-21)22-5-7-25(33)26(15-22)36-29(41)27-16-24(43-2)18-39(27)30(42)37-28-8-6-23(32)17-35-28/h5-8,10-11,13-15,17,20,24,27H,3-4,9,12,16,18H2,1-2H3,(H,36,41)(H,38,40)(H,35,37,42)/t24-,27-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433368
PNG
(US10562850, Compound 61b | US11066360, Compound 61...)
Show SMILES CC(C)(C)[S@](=O)NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1)c1ccccn1
Show InChI InChI=1S/C33H39ClFN5O4S/c1-32(2,3)45(44)39-33(16-15-21-7-8-21,29-6-4-5-17-36-29)22-9-14-26(35)27(18-22)38-30(42)28-19-25(41)20-40(28)31(43)37-24-12-10-23(34)11-13-24/h4-6,9-14,17-18,21,25,28,39,41H,7-8,15-16,19-20H2,1-3H3,(H,37,43)(H,38,42)/t25-,28-,33?,45+/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433407
PNG
(US10562850, Compound 14h | US11066360, Compound 14...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cn2)c1
Show InChI InChI=1S/C30H30ClFN6O3/c31-22-7-9-27(35-16-22)37-29(41)38-17-23(39)14-26(38)28(40)36-25-13-21(6-8-24(25)32)30(34,11-10-18-4-5-18)20-3-1-2-19(12-20)15-33/h1-3,6-9,12-13,16,18,23,26,39H,4-5,10-11,14,17,34H2,(H,36,40)(H,35,37,41)/t23-,26-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433415
PNG
(US10562850, Compound 30a | US11066360, Compound 30...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1
Show InChI InChI=1S/C37H35ClFN5O3/c38-29-12-14-30(15-13-29)42-35(46)44-23-36(47,26-6-2-1-3-7-26)21-33(44)34(45)43-32-20-28(11-16-31(32)39)37(41,18-17-24-9-10-24)27-8-4-5-25(19-27)22-40/h1-8,11-16,19-20,24,33,47H,9-10,17-18,21,23,41H2,(H,42,46)(H,43,45)/t33-,36-,37?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433428
PNG
(US10562850, Compound 38d | US11066360, Compound 38...)
Show SMILES CCC1(O)C[C@@H](N(C1)C(=O)OC(C)(C)C)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@@](=O)C(C)(C)C)c1ccccn1
Show InChI InChI=1S/C33H47FN4O5S/c1-8-32(41)20-26(38(21-32)29(40)43-30(2,3)4)28(39)36-25-19-23(14-15-24(25)34)33(17-16-22-12-13-22,27-11-9-10-18-35-27)37-44(42)31(5,6)7/h9-11,14-15,18-19,22,26,37,41H,8,12-13,16-17,20-21H2,1-7H3,(H,36,39)/t26-,32?,33?,44+/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433441
PNG
(US10562850, Compound 48d | US11066360, Compound 48...)
Show SMILES C[C@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C29H32ClFN6O2/c1-18-14-25(37(17-18)28(39)36-26-7-5-22(30)16-34-26)27(38)35-24-15-21(4-6-23(24)31)29(32,11-8-19-2-3-19)20-9-12-33-13-10-20/h4-7,9-10,12-13,15-16,18-19,25H,2-3,8,11,14,17,32H2,1H3,(H,35,38)(H,34,36,39)/t18-,25+,29?/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
<50n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433406
PNG
(US10562850, Compound 35a | US11066360, Compound 35...)
Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1)c1ccccc1
Show InChI InChI=1S/C35H36ClFN6O3/c1-46-34(24-7-3-2-4-8-24)20-29(43(22-34)33(45)42-31-15-13-26(36)21-40-31)32(44)41-28-19-25(12-14-27(28)37)35(38,17-16-23-10-11-23)30-9-5-6-18-39-30/h2-9,12-15,18-19,21,23,29H,10-11,16-17,20,22,38H2,1H3,(H,41,44)(H,40,42,45)/t29-,34-,35?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433449
PNG
(US10562850, Compound 42l | US10562850, Compound 43...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccccc1=O
Show InChI InChI=1S/C29H31ClFN5O4/c1-40-21-15-25(36(17-21)29(39)34-26-12-9-20(30)16-32-26)28(38)33-23-14-19(8-10-22(23)31)24(11-7-18-5-6-18)35-13-3-2-4-27(35)37/h2-4,8-10,12-14,16,18,21,24-25H,5-7,11,15,17H2,1H3,(H,33,38)(H,32,34,39)/t21-,24?,25-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433438
PNG
(US10562850, Compound 47d | US11066360, Compound 47...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1
Show InChI InChI=1S/C34H34ClFN6O2/c35-27-9-11-31(39-20-27)41-33(44)42-21-24(23-4-2-1-3-5-23)18-30(42)32(43)40-29-19-26(8-10-28(29)36)34(37,15-12-22-6-7-22)25-13-16-38-17-14-25/h1-5,8-11,13-14,16-17,19-20,22,24,30H,6-7,12,15,18,21,37H2,(H,40,43)(H,39,41,44)/t24-,30+,34?/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433366
PNG
(US10562850, Compound 1p | US10562850, Compound 3a ...)
Show SMILES O[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1
Show InChI InChI=1S/C29H30ClFN4O3/c30-21-9-11-22(12-10-21)33-29(38)35-17-23(36)15-26(35)28(37)34-25-14-20(8-13-24(25)31)27(32-16-18-6-7-18)19-4-2-1-3-5-19/h1-5,8-14,18,23,26-27,32,36H,6-7,15-17H2,(H,33,38)(H,34,37)/t23-,26-,27?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433367
PNG
(US10562850, Compound 17b | US11066360, Compound 17...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C32H33ClFN5O3/c1-42-26-17-29(39(19-26)31(41)37-25-10-8-24(33)9-11-25)30(40)38-28-16-23(7-12-27(28)34)32(36,14-13-20-5-6-20)22-4-2-3-21(15-22)18-35/h2-4,7-12,15-16,20,26,29H,5-6,13-14,17,19,36H2,1H3,(H,37,41)(H,38,40)/t26-,29-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433375
PNG
(US10562850, Compound 4g | US11066360, Compound 4g)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H31ClFN5O3/c32-23-7-9-24(10-8-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(6-11-26(27)33)31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,35H2,(H,36,41)(H,37,40)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433459
PNG
(US10562850, Compound 80c | US11066360, Compound 80...)
Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@H]3C[C@H]3N2)c1
Show InChI InChI=1S/C23H27FN4O/c24-18-4-3-17(13-20(18)28-22(29)21-12-15-11-19(15)27-21)23(25,8-5-14-1-2-14)16-6-9-26-10-7-16/h3-4,6-7,9-10,13-15,19,21,27H,1-2,5,8,11-12,25H2,(H,28,29)/t15-,19-,21-,23?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433424
PNG
(US10562850, Compound 4f | US11066360, Compound 4f)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C35H39ClFN5O4S/c1-34(2,3)47(46)41-35(16-15-22-7-8-22,24-6-4-5-23(17-24)20-38)25-9-14-29(37)30(18-25)40-32(44)31-19-28(43)21-42(31)33(45)39-27-12-10-26(36)11-13-27/h4-6,9-14,17-18,22,28,31,41,43H,7-8,15-16,19,21H2,1-3H3,(H,39,45)(H,40,44)/t28-,31-,35?,47-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433371
PNG
(US10562850, Compound 30b | US11066360, Compound 30...)
Show SMILES O[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NC(=O)Nc1ccc(Cl)cc1)c1cccc(c1)C#N)c1ccccc1
Show InChI InChI=1S/C44H39Cl2FN6O4/c45-33-12-16-35(17-13-33)49-41(55)52-44(22-21-28-9-10-28,31-8-4-5-29(23-31)26-48)32-11-20-37(47)38(24-32)51-40(54)39-25-43(57,30-6-2-1-3-7-30)27-53(39)42(56)50-36-18-14-34(46)15-19-36/h1-8,11-20,23-24,28,39,57H,9-10,21-22,25,27H2,(H,50,56)(H,51,54)(H2,49,52,55)/t39-,43-,44?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433445
PNG
(US10562850, Compound 49d | US11066360, Compound 49...)
Show SMILES C[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C29H32ClFN6O2/c1-18-14-25(37(17-18)28(39)36-26-7-5-22(30)16-34-26)27(38)35-24-15-21(4-6-23(24)31)29(32,11-8-19-2-3-19)20-9-12-33-13-10-20/h4-7,9-10,12-13,15-16,18-19,25H,2-3,8,11,14,17,32H2,1H3,(H,35,38)(H,34,36,39)/t18-,25-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433377
PNG
(US10562850, Compound 63g | US11066360, Compound 63...)
Show SMILES NC(CCC1CC1)(c1ccc(cc1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H31ClFN5O3/c32-23-8-10-24(11-9-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(7-12-26(27)33)31(35,14-13-19-1-2-19)21-5-3-20(17-34)4-6-21/h3-12,15,19,25,28,39H,1-2,13-14,16,18,35H2,(H,36,41)(H,37,40)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433393
PNG
(US10562850, Compound 23b | US11066360, Compound 23...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Br)cc2)c1
Show InChI InChI=1S/C31H31BrFN5O3/c32-23-7-9-24(10-8-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(6-11-26(27)33)31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,35H2,(H,36,41)(H,37,40)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
75n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433383
PNG
(US10562850, Compound 6f | US11066360, Compound 6f)
Show SMILES CO[C@@H]1C[C@H](N(C1)C(=O)N(C)c1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C33H35ClFN5O3/c1-39(26-11-9-25(34)10-12-26)32(42)40-20-27(43-2)18-30(40)31(41)38-29-17-24(8-13-28(29)35)33(37,15-14-21-6-7-21)23-5-3-4-22(16-23)19-36/h3-5,8-13,16-17,21,27,30H,6-7,14-15,18,20,37H2,1-2H3,(H,38,41)/t27-,30+,33?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433384
PNG
(US10562850, Compound 20b | US11066360, Compound 20...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2CC(=O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H29ClFN5O3/c32-23-7-9-24(10-8-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(6-11-26(27)33)31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,28H,4-5,12-13,16,18,35H2,(H,36,41)(H,37,40)/t28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433387
PNG
(US10562850, Compound 21d | US11066360, Compound 21...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccccc2)c1
Show InChI InChI=1S/C31H32FN5O3/c32-26-12-11-23(31(34,14-13-20-9-10-20)22-6-4-5-21(15-22)18-33)16-27(26)36-29(39)28-17-25(38)19-37(28)30(40)35-24-7-2-1-3-8-24/h1-8,11-12,15-16,20,25,28,38H,9-10,13-14,17,19,34H2,(H,35,40)(H,36,39)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433389
PNG
(US10562850, Compound 7c | US11066360, Compound 7c)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2CCCN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H31ClFN5O2/c32-24-9-11-25(12-10-24)36-30(40)38-16-2-5-28(38)29(39)37-27-18-23(8-13-26(27)33)31(35,15-14-20-6-7-20)22-4-1-3-21(17-22)19-34/h1,3-4,8-13,17-18,20,28H,2,5-7,14-16,35H2,(H,36,40)(H,37,39)/t28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433402
PNG
(US10562850, Compound 26b | US11066360, Compound 26...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2cccc3ccccc23)c1
Show InChI InChI=1S/C35H34FN5O3/c36-29-14-13-26(35(38,16-15-22-11-12-22)25-8-3-5-23(17-25)20-37)18-31(29)39-33(43)32-19-27(42)21-41(32)34(44)40-30-10-4-7-24-6-1-2-9-28(24)30/h1-10,13-14,17-18,22,27,32,42H,11-12,15-16,19,21,38H2,(H,39,43)(H,40,44)/t27-,32-,35?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433411
PNG
(US10562850, Compound 15f | US11066360, Compound 15...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(cc1)C#N)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C33H33FN6O3/c1-43-27-17-30(40(20-27)32(42)38-26-10-7-22(18-35)8-11-26)31(41)39-29-16-25(9-12-28(29)34)33(37,14-13-21-5-6-21)24-4-2-3-23(15-24)19-36/h2-4,7-12,15-16,21,27,30H,5-6,13-14,17,20,37H2,1H3,(H,38,42)(H,39,41)/t27-,30-,33?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433417
PNG
(US10562850, Compound 60a | US11066360, Compound 60...)
Show SMILES O[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)[C@H](NCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C30H29ClFN5O3/c31-22-7-9-23(10-8-22)35-30(40)37-17-24(38)14-27(37)29(39)36-26-13-21(6-11-25(26)32)28(34-16-18-4-5-18)20-3-1-2-19(12-20)15-33/h1-3,6-13,18,24,27-28,34,38H,4-5,14,16-17H2,(H,35,40)(H,36,39)/t24-,27-,28-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433471
PNG
(US10562850, Compound 85a | US11066360, Compound 85...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)c1ccc(F)c(N)c1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C30H33F2N5O3/c1-40-22-16-27(37(17-22)29(39)19-4-6-23(31)25(33)14-19)28(38)36-26-15-21(5-7-24(26)32)30(34,11-8-18-2-3-18)20-9-12-35-13-10-20/h4-7,9-10,12-15,18,22,27H,2-3,8,11,16-17,33-34H2,1H3,(H,36,38)/t22-,27-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433376
PNG
(US10562850, Compound 19c | US11066360, Compound 19...)
Show SMILES N[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C31H32ClFN6O2/c32-23-7-9-25(10-8-23)37-30(41)39-18-24(35)16-28(39)29(40)38-27-15-22(6-11-26(27)33)31(36,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,24,28H,4-5,12-13,16,18,35-36H2,(H,37,41)(H,38,40)/t24-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433392
PNG
(US10562850, Compound 8c | US11066360, Compound 8c)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@@H]2CCCN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H31ClFN5O2/c32-24-9-11-25(12-10-24)36-30(40)38-16-2-5-28(38)29(39)37-27-18-23(8-13-26(27)33)31(35,15-14-20-6-7-20)22-4-1-3-21(17-22)19-34/h1,3-4,8-13,17-18,20,28H,2,5-7,14-16,35H2,(H,36,40)(H,37,39)/t28-,31?/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433420
PNG
(US10562850, Compound 76e | US11066360, Compound 76...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Cc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C31H34ClFN4O3/c1-40-25-18-28(37(19-25)29(38)16-21-4-7-24(32)8-5-21)30(39)36-27-17-23(6-9-26(27)33)31(34,13-10-20-2-3-20)22-11-14-35-15-12-22/h4-9,11-12,14-15,17,20,25,28H,2-3,10,13,16,18-19,34H2,1H3,(H,36,39)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433433
PNG
(US10562850, Compound 12b | US11066360, Compound 12...)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2CCCN2C(=O)OCc2ccccc2)c1
Show InChI InChI=1S/C36H41FN4O4S/c1-35(2,3)46(44)40-36(19-18-25-14-15-25,28-12-7-11-27(21-28)23-38)29-16-17-30(37)31(22-29)39-33(42)32-13-8-20-41(32)34(43)45-24-26-9-5-4-6-10-26/h4-7,9-12,16-17,21-22,25,32,40H,8,13-15,18-20,24H2,1-3H3,(H,39,42)/t32-,36?,46-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433467
PNG
(US10562850, Compound 7b | US11066360, Compound 7b)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2CCCN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C35H39ClFN5O3S/c1-34(2,3)46(45)41-35(18-17-23-9-10-23,25-7-4-6-24(20-25)22-38)26-11-16-29(37)30(21-26)40-32(43)31-8-5-19-42(31)33(44)39-28-14-12-27(36)13-15-28/h4,6-7,11-16,20-21,23,31,41H,5,8-10,17-19H2,1-3H3,(H,39,44)(H,40,43)/t31-,35?,46-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433366
PNG
(US10562850, Compound 1p | US10562850, Compound 3a ...)
Show SMILES O[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1
Show InChI InChI=1S/C29H30ClFN4O3/c30-21-9-11-22(12-10-21)33-29(38)35-17-23(36)15-26(35)28(37)34-25-14-20(8-13-24(25)31)27(32-16-18-6-7-18)19-4-2-1-3-5-19/h1-5,8-14,18,23,26-27,32,36H,6-7,15-17H2,(H,33,38)(H,34,37)/t23-,26-,27?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433379
PNG
(US10562850, Compound 33d | US11066360, Compound 33...)
Show SMILES N[C@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C31H32ClFN6O2/c32-23-7-9-25(10-8-23)37-30(41)39-18-24(35)16-28(39)29(40)38-27-15-22(6-11-26(27)33)31(36,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,24,28H,4-5,12-13,16,18,35-36H2,(H,37,41)(H,38,40)/t24-,28+,31?/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433390
PNG
(US10562850, Compound 22b | US11066360, Compound 22...)
Show SMILES Cc1ccc(NC(=O)N2C[C@H](O)C[C@@H]2C(=O)Nc2cc(ccc2F)C(N)(CCC2CC2)c2cccc(c2)C#N)cc1
Show InChI InChI=1S/C32H34FN5O3/c1-20-5-10-25(11-6-20)36-31(41)38-19-26(39)17-29(38)30(40)37-28-16-24(9-12-27(28)33)32(35,14-13-21-7-8-21)23-4-2-3-22(15-23)18-34/h2-6,9-12,15-16,21,26,29,39H,7-8,13-14,17,19,35H2,1H3,(H,36,41)(H,37,40)/t26-,29-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM504563
PNG
(US11066360, Compound 16b)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(OC)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C33H36FN5O4/c1-42-26-11-9-25(10-12-26)37-32(41)39-20-27(43-2)18-30(39)31(40)38-29-17-24(8-13-28(29)34)33(36,15-14-21-6-7-21)23-5-3-4-22(16-23)19-35/h3-5,8-13,16-17,21,27,30H,6-7,14-15,18,20,36H2,1-2H3,(H,37,41)(H,38,40)/t27-,30-,33?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433468
PNG
(US10562850, Compound 84a | US11066360, Compound 84...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)c1ccc(Cl)c(N)c1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C30H33ClFN5O3/c1-40-22-16-27(37(17-22)29(39)19-4-6-23(31)25(33)14-19)28(38)36-26-15-21(5-7-24(26)32)30(34,11-8-18-2-3-18)20-9-12-35-13-10-20/h4-7,9-10,12-15,18,22,27H,2-3,8,11,16-17,33-34H2,1H3,(H,36,38)/t22-,27-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433378
PNG
(US10562850, Compound 5e | US11066360, Compound 5e)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H31ClFN5O3/c32-23-7-9-24(10-8-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(6-11-26(27)33)31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,35H2,(H,36,41)(H,37,40)/t25-,28+,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
KEGG
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433409
PNG
(US10562850, Compound 66c | US11066360, Compound 66...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@](=O)C(C)(C)C)c1ccccc1
Show InChI InChI=1S/C34H41ClFN5O4S/c1-33(2,3)46(44)40-34(17-16-22-10-11-22,23-8-6-5-7-9-23)24-12-14-27(36)28(18-24)38-31(42)29-19-26(45-4)21-41(29)32(43)39-30-15-13-25(35)20-37-30/h5-9,12-15,18,20,22,26,29,40H,10-11,16-17,19,21H2,1-4H3,(H,38,42)(H,37,39,43)/t26-,29-,34?,46-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433388
PNG
(BDBM433391 | US10562850, Compound 36d | US10562850...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1
Show InChI InChI=1S/C29H32ClFN6O3/c1-40-21-15-24(37(17-21)28(39)36-26-10-8-20(30)16-34-26)27(38)35-23-14-19(7-9-22(23)31)29(32,12-11-18-5-6-18)25-4-2-3-13-33-25/h2-4,7-10,13-14,16,18,21,24H,5-6,11-12,15,17,32H2,1H3,(H,35,38)(H,34,36,39)/t21-,24-,29?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433395
PNG
(US10562850, Compound 9c | US11066360, Compound 9c)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H31ClFN5O3/c32-23-7-9-24(10-8-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(6-11-26(27)33)31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,35H2,(H,36,41)(H,37,40)/t25-,28+,31?/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433425
PNG
(US10562850, Compound 67b | US11066360, Compound 67...)
Show SMILES CCNC(CCC1CC1)(c1ccccc1)c1ccc(F)c(NC(=O)[C@H]2C[C@H](CN2C(=O)Nc2ccc(Cl)cn2)OC)c1
Show InChI InChI=1S/C32H37ClFN5O3/c1-3-36-32(16-15-21-9-10-21,22-7-5-4-6-8-22)23-11-13-26(34)27(17-23)37-30(40)28-18-25(42-2)20-39(28)31(41)38-29-14-12-24(33)19-35-29/h4-8,11-14,17,19,21,25,28,36H,3,9-10,15-16,18,20H2,1-2H3,(H,37,40)(H,35,38,41)/t25-,28-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433427
PNG
(US10562850, Compound 9b | US11066360, Compound 9b)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C35H39ClFN5O4S/c1-34(2,3)47(46)41-35(16-15-22-7-8-22,24-6-4-5-23(17-24)20-38)25-9-14-29(37)30(18-25)40-32(44)31-19-28(43)21-42(31)33(45)39-27-12-10-26(36)11-13-27/h4-6,9-14,17-18,22,28,31,41,43H,7-8,15-16,19,21H2,1-3H3,(H,39,45)(H,40,44)/t28-,31+,35?,47+/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433444
PNG
(US10562850, Compound 33b | US11066360, Compound 33...)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](CN2C(=O)Nc2ccc(Cl)cc2)N=[N+]=[N-])c1
Show InChI InChI=1S/C35H38ClFN8O3S/c1-34(2,3)49(48)43-35(16-15-22-7-8-22,24-6-4-5-23(17-24)20-38)25-9-14-29(37)30(18-25)41-32(46)31-19-28(42-44-39)21-45(31)33(47)40-27-12-10-26(36)11-13-27/h4-6,9-14,17-18,22,28,31,43H,7-8,15-16,19,21H2,1-3H3,(H,40,47)(H,41,46)/t28-,31+,35?,49+/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433446
PNG
(US10562850, Compound 44e | US11066360, Compound 44...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)N1CCCCC1=O
Show InChI InChI=1S/C29H35ClFN5O4/c1-40-21-15-25(36(17-21)29(39)34-26-12-9-20(30)16-32-26)28(38)33-23-14-19(8-10-22(23)31)24(11-7-18-5-6-18)35-13-3-2-4-27(35)37/h8-10,12,14,16,18,21,24-25H,2-7,11,13,15,17H2,1H3,(H,33,38)(H,32,34,39)/t21-,24?,25-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433472
PNG
(US10562850, Compound 86a | US11066360, Compound 86...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)c1cccc(c1)C#N)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C31H32FN5O3/c1-40-25-17-28(37(19-25)30(39)22-4-2-3-21(15-22)18-33)29(38)36-27-16-24(7-8-26(27)32)31(34,12-9-20-5-6-20)23-10-13-35-14-11-23/h2-4,7-8,10-11,13-16,20,25,28H,5-6,9,12,17,19,34H2,1H3,(H,36,38)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433401
PNG
(US10562850, Compound 11e | US11066360, Compound 11...)
Show SMILES CO[C@H]1C[C@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C32H33ClFN5O3/c1-42-26-17-29(39(19-26)31(41)37-25-10-8-24(33)9-11-25)30(40)38-28-16-23(7-12-27(28)34)32(36,14-13-20-5-6-20)22-4-2-3-21(15-22)18-35/h2-4,7-12,15-16,20,26,29H,5-6,13-14,17,19,36H2,1H3,(H,37,41)(H,38,40)/t26-,29-,32?/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433405
PNG
(US10562850, Compound 27b | US11066360, Compound 27...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(cc2)C(F)(F)F)c1
Show InChI InChI=1S/C32H31F4N5O3/c33-26-11-8-23(31(38,13-12-19-4-5-19)22-3-1-2-20(14-22)17-37)15-27(26)40-29(43)28-16-25(42)18-41(28)30(44)39-24-9-6-21(7-10-24)32(34,35)36/h1-3,6-11,14-15,19,25,28,42H,4-5,12-13,16,18,38H2,(H,39,44)(H,40,43)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433440
PNG
(US10562850, Compound 29d | US11066360, Compound 29...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2)c2ccccc2)c1
Show InChI InChI=1S/C30H31FN4O2/c31-25-12-11-24(30(33,14-13-20-9-10-20)23-8-4-5-21(15-23)18-32)16-26(25)35-28(36)27-17-29(37,19-34-27)22-6-2-1-3-7-22/h1-8,11-12,15-16,20,27,34,37H,9-10,13-14,17,19,33H2,(H,35,36)/t27-,29-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433447
PNG
(US10562850, Compound 34b | US11066360, Compound 34...)
Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)OC(C)(C)C)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@@](=O)C(C)(C)C)c1ccccn1)c1ccccc1
Show InChI InChI=1S/C38H49FN4O5S/c1-35(2,3)48-34(45)43-25-37(47-7,27-13-9-8-10-14-27)24-31(43)33(44)41-30-23-28(18-19-29(30)39)38(21-20-26-16-17-26,32-15-11-12-22-40-32)42-49(46)36(4,5)6/h8-15,18-19,22-23,26,31,42H,16-17,20-21,24-25H2,1-7H3,(H,41,44)/t31-,37-,38?,49+/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433452
PNG
(US10562850, Compound 45c | US11066360, Compound 45...)
Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)c1ccccc1
Show InChI InChI=1S/C35H36ClFN6O3/c1-46-34(24-5-3-2-4-6-24)20-30(43(22-34)33(45)42-31-12-10-27(36)21-40-31)32(44)41-29-19-26(9-11-28(29)37)35(38,16-13-23-7-8-23)25-14-17-39-18-15-25/h2-6,9-12,14-15,17-19,21,23,30H,7-8,13,16,20,22,38H2,1H3,(H,41,44)(H,40,42,45)/t30-,34-,35?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433458
PNG
(US10562850, Compound 5d | US11066360, Compound 5d)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C35H39ClFN5O4S/c1-34(2,3)47(46)41-35(16-15-22-7-8-22,24-6-4-5-23(17-24)20-38)25-9-14-29(37)30(18-25)40-32(44)31-19-28(43)21-42(31)33(45)39-27-12-10-26(36)11-13-27/h4-6,9-14,17-18,22,28,31,41,43H,7-8,15-16,19,21H2,1-3H3,(H,39,45)(H,40,44)/t28-,31+,35?,47-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
KEGG
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433386
PNG
(US10562850, Compound 6e | US11066360, Compound 6e)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)N(C)c1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C33H35ClFN5O3/c1-39(26-11-9-25(34)10-12-26)32(42)40-20-27(43-2)18-30(40)31(41)38-29-17-24(8-13-28(29)35)33(37,15-14-21-6-7-21)23-5-3-4-22(16-23)19-36/h3-5,8-13,16-17,21,27,30H,6-7,14-15,18,20,37H2,1-2H3,(H,38,41)/t27-,30-,33?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433399
PNG
(US10562850, Compound 25b | US11066360, Compound 25...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(cc2)[N+]([O-])=O)c1
Show InChI InChI=1S/C31H31FN6O5/c32-26-11-6-22(31(34,13-12-19-4-5-19)21-3-1-2-20(14-21)17-33)15-27(26)36-29(40)28-16-25(39)18-37(28)30(41)35-23-7-9-24(10-8-23)38(42)43/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,34H2,(H,35,41)(H,36,40)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
KEGG
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433430
PNG
(US10562850, Compound 11d | US11066360, Compound 11...)
Show SMILES CO[C@H]1C[C@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@](=O)C(C)(C)C)c1cccc(c1)C#N
Show InChI InChI=1S/C36H41ClFN5O4S/c1-35(2,3)48(46)42-36(17-16-23-8-9-23,25-7-5-6-24(18-25)21-39)26-10-15-30(38)31(19-26)41-33(44)32-20-29(47-4)22-43(32)34(45)40-28-13-11-27(37)12-14-28/h5-7,10-15,18-19,23,29,32,42H,8-9,16-17,20,22H2,1-4H3,(H,40,45)(H,41,44)/t29-,32-,36?,48+/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433436
PNG
(US10562850, Compound 27a | US11066360, Compound 27...)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(cc2)C(F)(F)F)c1
Show InChI InChI=1S/C36H39F4N5O4S/c1-34(2,3)50(49)44-35(16-15-22-7-8-22,25-6-4-5-23(17-25)20-41)26-11-14-29(37)30(18-26)43-32(47)31-19-28(46)21-45(31)33(48)42-27-12-9-24(10-13-27)36(38,39)40/h4-6,9-14,17-18,22,28,31,44,46H,7-8,15-16,19,21H2,1-3H3,(H,42,48)(H,43,47)/t28-,31-,35?,50-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433462
PNG
(US10562850, Compound 82a | US11066360, Compound 82...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)c1ccc2cc[nH]c2c1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C32H34FN5O3/c1-41-25-18-29(38(19-25)31(40)22-5-4-21-9-15-36-27(21)16-22)30(39)37-28-17-24(6-7-26(28)33)32(34,12-8-20-2-3-20)23-10-13-35-14-11-23/h4-7,9-11,13-17,20,25,29,36H,2-3,8,12,18-19,34H2,1H3,(H,37,39)/t25-,29-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433473
PNG
(US10562850, Compound 87b | US11066360, Compound 87...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)S(=O)(=O)c1cccc2c(Cl)cccc12)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@](=O)C(C)(C)C)c1ccncc1
Show InChI InChI=1S/C37H42ClFN4O5S2/c1-36(2,3)49(45)42-37(18-15-24-11-12-24,25-16-19-40-20-17-25)26-13-14-31(39)32(21-26)41-35(44)33-22-27(48-4)23-43(33)50(46,47)34-10-6-7-28-29(34)8-5-9-30(28)38/h5-10,13-14,16-17,19-21,24,27,33,42H,11-12,15,18,22-23H2,1-4H3,(H,41,44)/t27-,33-,37?,49-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433369
PNG
(US10562850, Compound 2a | US11066360, Compound 2a)
Show SMILES O[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1ccccc1F
Show InChI InChI=1S/C18H17ClFN3O3/c19-11-5-7-12(8-6-11)21-18(26)23-10-13(24)9-16(23)17(25)22-15-4-2-1-3-14(15)20/h1-8,13,16,24H,9-10H2,(H,21,26)(H,22,25)/t13-,16-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433396
PNG
(US10562850, Compound 24b | US11066360, Compound 24...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(F)cc2)c1
Show InChI InChI=1S/C31H31F2N5O3/c32-23-7-9-24(10-8-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(6-11-26(27)33)31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,35H2,(H,36,41)(H,37,40)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433398
PNG
(US10562850, Compound 10c | US11066360, Compound 10...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@@H]2C[C@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C31H31ClFN5O3/c32-23-7-9-24(10-8-23)36-30(41)38-18-25(39)16-28(38)29(40)37-27-15-22(6-11-26(27)33)31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-34/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,35H2,(H,36,41)(H,37,40)/t25-,28-,31?/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433400
PNG
(US10562850, Compound 32b | US11066360, Compound 32...)
Show SMILES O[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NC(=O)Nc1ccc(Cl)cn1)c1ccccn1)c1ccccc1
Show InChI InChI=1S/C40H37Cl2FN8O4/c41-28-12-15-34(45-22-28)48-37(53)50-40(18-17-25-9-10-25,33-8-4-5-19-44-33)27-11-14-30(43)31(20-27)47-36(52)32-21-39(55,26-6-2-1-3-7-26)24-51(32)38(54)49-35-16-13-29(42)23-46-35/h1-8,11-16,19-20,22-23,25,32,55H,9-10,17-18,21,24H2,(H,47,52)(H,46,49,54)(H2,45,48,50,53)/t32-,39-,40?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433404
PNG
(US10562850, Compound 13e | US11066360, Compound 13...)
Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2CCCN2C(=O)Nc2ccc(Cl)cn2)c1
Show InChI InChI=1S/C30H30ClFN6O2/c31-23-9-11-27(35-18-23)37-29(40)38-14-2-5-26(38)28(39)36-25-16-22(8-10-24(25)32)30(34,13-12-19-6-7-19)21-4-1-3-20(15-21)17-33/h1,3-4,8-11,15-16,18-19,26H,2,5-7,12-14,34H2,(H,36,39)(H,35,37,40)/t26-,30?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433408
PNG
(US10562850, Compound 28b | US11066360, Compound 28...)
Show SMILES Nc1ccc(NC(=O)N2C[C@H](O)C[C@@H]2C(=O)Nc2cc(ccc2F)C(N)(CCC2CC2)c2cccc(c2)C#N)cc1
Show InChI InChI=1S/C31H33FN6O3/c32-26-11-6-22(31(35,13-12-19-4-5-19)21-3-1-2-20(14-21)17-33)15-27(26)37-29(40)28-16-25(39)18-38(28)30(41)36-24-9-7-23(34)8-10-24/h1-3,6-11,14-15,19,25,28,39H,4-5,12-13,16,18,34-35H2,(H,36,41)(H,37,40)/t25-,28-,31?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433414
PNG
(US10562850, Compound 14g | US11066360, Compound 14...)
Show SMILES CC(=O)O[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N
Show InChI InChI=1S/C32H32ClFN6O4/c1-19(41)44-25-15-28(40(18-25)31(43)39-29-10-8-24(33)17-37-29)30(42)38-27-14-23(7-9-26(27)34)32(36,12-11-20-5-6-20)22-4-2-3-21(13-22)16-35/h2-4,7-10,13-14,17,20,25,28H,5-6,11-12,15,18,36H2,1H3,(H,38,42)(H,37,39,43)/t25-,28-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433421
PNG
(US10562850, Compound 10b | US11066360, Compound 10...)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@@H]2C[C@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C35H39ClFN5O4S/c1-34(2,3)47(46)41-35(16-15-22-7-8-22,24-6-4-5-23(17-24)20-38)25-9-14-29(37)30(18-25)40-32(44)31-19-28(43)21-42(31)33(45)39-27-12-10-26(36)11-13-27/h4-6,9-14,17-18,22,28,31,41,43H,7-8,15-16,19,21H2,1-3H3,(H,39,45)(H,40,44)/t28-,31-,35?,47+/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433461
PNG
(US10562850, Compound 6d | US11066360, Compound 6d)
Show SMILES CO[C@@H]1C[C@H](N(C1)C(=O)N(C)c1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@](=O)C(C)(C)C)c1cccc(c1)C#N
Show InChI InChI=1S/C37H43ClFN5O4S/c1-36(2,3)49(47)42-37(18-17-24-9-10-24,26-8-6-7-25(19-26)22-40)27-11-16-31(39)32(20-27)41-34(45)33-21-30(48-5)23-44(33)35(46)43(4)29-14-12-28(38)13-15-29/h6-8,11-16,19-20,24,30,33,42H,9-10,17-18,21,23H2,1-5H3,(H,41,45)/t30-,33+,37?,49-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433464
PNG
(US10562850, Compound 6c | US11066360, Compound 6c)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)N(C)c1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@](=O)C(C)(C)C)c1cccc(c1)C#N
Show InChI InChI=1S/C37H43ClFN5O4S/c1-36(2,3)49(47)42-37(18-17-24-9-10-24,26-8-6-7-25(19-26)22-40)27-11-16-31(39)32(20-27)41-34(45)33-21-30(48-5)23-44(33)35(46)43(4)29-14-12-28(38)13-15-29/h6-8,11-16,19-20,24,30,33,42H,9-10,17-18,21,23H2,1-5H3,(H,41,45)/t30-,33-,37?,49-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433465
PNG
(US10562850, Compound 83a | US11066360, Compound 83...)
Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)c1ccc2c(Cl)c[nH]c2c1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1
Show InChI InChI=1S/C32H33ClFN5O3/c1-42-23-16-29(39(18-23)31(41)20-4-6-24-25(33)17-37-27(24)14-20)30(40)38-28-15-22(5-7-26(28)34)32(35,11-8-19-2-3-19)21-9-12-36-13-10-21/h4-7,9-10,12-15,17,19,23,29,37H,2-3,8,11,16,18,35H2,1H3,(H,38,40)/t23-,29-,32?/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM433470
PNG
(US10562850, Compound 8b | US11066360, Compound 8b)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@@H]2CCCN2C(=O)Nc2ccc(Cl)cc2)c1
Show InChI InChI=1S/C35H39ClFN5O3S/c1-34(2,3)46(45)41-35(18-17-23-9-10-23,25-7-4-6-24(20-25)22-38)26-11-16-29(37)30(21-26)40-32(43)31-8-5-19-42(31)33(44)39-28-14-12-27(36)13-15-28/h4,6-7,11-16,20-21,23,31,41H,5,8-10,17-19H2,1-3H3,(H,39,44)(H,40,43)/t31-,35?,46+/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
>100n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US11066360 (2021)

More data for this
Ligand-Target Pair
* indicates data uncertainty>20%